Propanc Biopharma Grants 3.5M Restricted Shares to Insiders and Consultants
PPCB is trading near its 52-week low of $0.95 (3.0% below the low).
Summary
Propanc Biopharma plans to issue 3.5 million restricted shares to insiders and consultants, nearly doubling its outstanding shares. The CEO receives 1 million shares, and the issuance was approved by the CEO as majority stockholder without a shareholder vote.
Key Events · Executive and Board Changes · PPCB
-
3.5M Restricted Shares Issued to Insiders
The company will issue 3.5 million restricted shares to officers, directors, and consultants, nearly doubling the outstanding share count from 3.5 million to 7.0 million. CEO James Nathanielsz receives 1 million shares.
-
Massive Dilution for Existing Shareholders
The issuance represents approximately 100% dilution. At the current stock price of $0.9215, the total grant value is roughly $3.2 million, exceeding the company's market cap.
-
CEO Controls Approval Process
The issuance was approved by written consent of the majority stockholder, who is CEO James Nathanielsz, holding 50.001% voting power. No shareholder meeting was held.
-
NASDAQ Compliance Requirement Met
Stockholder approval was obtained under NASDAQ Listing Rule 5635(c) for the equity compensation arrangement, maintaining listing compliance.
Analysis · PPCB · Life Sciences
The company is issuing 3.5 million restricted shares to officers, directors, and service providers as equity compensation. This nearly doubles the outstanding share count from 3.5 million to 7.0 million, representing massive dilution for existing shareholders. The issuance was approved by the majority stockholder (CEO James Nathanielsz) via written consent, bypassing a shareholder meeting. While the shares are restricted and not immediately tradable, the sheer size of the grant — especially 1 million shares to the CEO — raises governance concerns, particularly given the company's micro-cap status and recent reverse stock split.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 29.7% of the 1695 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPCB was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.95 to $270.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.